Prescient Therapeutics initiates first US site for Phase 2a trial of PTX-100 in CTCL
The first United States clinical trial site for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF)’s Phase 2a study...
The first United States clinical trial site for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF)’s Phase 2a study...
Prescient Therapeutics has crossed a major milestone in its international expansion, with the first US...
Stockhead’s Tylah Tully catches up with Prescient Therapeutics (ASX:PTX) CEO James McDonnell after the company hit a...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics CEO James McDonnell talked with Proactive about promising developments surrounding the company’s lead...
For those affected by Cutaneous T-Cell Lymphoma (CTCL), a rare and aggressive cancer, treatment options...
Prescient Therapeutics is focused on development of lead compound PTX-100 to treat rare blood cancer
In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX),...
Highlights,PTX-100 enters Phase 2 trial for relapsed and refractory Cutaneous T-Cell Lymphoma, Analysts lift valuation...
What is Relapsed or Refractory T-Cell Lymphoma? Why is it so difficult to treat? What...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.